ArticleJournal of virology2005
Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- MHC class I trafficking signal improves induction of cytotoxic T lymphocyte using artificial antigen presenting cells.Biochemistry and biophysics reports · 2025Article
- Dendritic Cells, the Double Agent in the War Against HIV-1.Frontiers in immunology · 2019Review
- Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?Frontiers in immunology · 2018Review
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.Vaccines · 2016Review
- Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.Forum on immunopathological diseases and therapeutics · 2015Article
- Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1.Journal of virology · 2014Article
- Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.PloS one · 2012Article
- Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.Journal of translational medicine · 2010Article
- Burkitt lymphoma: pathogenesis and immune evasion.Journal of oncology · 2010Article
- Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.Clinical and vaccine immunology : CVI · 2009Article
- Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells.Journal of virology · 2009Article
- Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.Clinical and vaccine immunology : CVI · 2009Article
- Dendritic cell-based human immunodeficiency virus vaccine.Journal of internal medicine · 2009Review
- Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.Journal of virology · 2009Article
- Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection.Clinical and vaccine immunology : CVI · 2007Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Dendritic cells (DCs) loaded with viral peptides are a potential form of immunotherapy of human immunodeficiency virus type 1 (HIV-1) infection. We show that DCs derived from blood monocytes of subjects with chronic HIV-1 infection on combination antiretroviral drug therapy have increases in expression of HLA, T-cell coreceptor, and T-cell activation molecules in response to the DC maturation factor CD40L comparable to those from uninfected persons. Mature DCs (mDCs) loaded with HLA A*0201-restricted viral peptides of the optimal length (9-mer) were more efficient at activating antiviral CD8(+) T cells than were immature DCs or peptide alone. Optimal presentation of these exogenous peptides required uptake and vesicular trafficking and was comparable in DCs derived from HIV-1-infected and uninfected persons. Furthermore, DCs from HIV-1-infected and uninfected persons had similar capacities to process viral peptides with C-terminal and N-terminal extensions through their proteasomal and cytosolic pathways, respectively. We conclude that DCs derived from HIV-1-infected persons have similar abilities to process exogenous peptides for presentation to CD8(+) T cells as those from uninfected persons. This conclusion supports the use of DCs loaded with synthetic peptides in immunotherapy of HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.